GlassScriptPhysician profile
Tara Ramachandra
NPI 1801039516
$1,593.17
in general payments reported to CMS, 2019-2025
29 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $80.35 · 2021: $34.38 · 2023: $24.07 · 2024: $1,023 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $167.04 | 2024 | |
| Janssen Scientific Affairs, LLC | $139.85 | 2024 | Tremfya |
| Lilly USA, LLC | $126.40 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Intersect Ent, INC. | $124.96 | 2019 | |
| Dermavant Sciences, INC. | $115.08 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $110.53 | 2023-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $100.56 | 2024 | Adbry |
| Ucb, INC. | $100.40 | 2024 | Bimzelx |
| Janssen Biotech, INC. | $90.19 | 2024 | Tremfya |
| Organogenesis INC. | $75.16 | 2024-2025 | Apligraf |
| Stryker Corporation | $47.18 | 2019-2020 | |
| Optinose US, INC. | $46.48 | 2019-2020 | |
| Incyte Corporation | $31.73 | 2024 | Opzelura |
| Csl Behring | $27.55 | 2025 | Hizentra |
| Cardinal Health 200 LLC | $26.83 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.64 | 2024 | Otezla |
| Kerecis Limited | $24.04 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Tms Neurohealth Centers INC. | $23.55 | 2025 | Tms Neurohealth Centers INC. |
| Arcutis Biotherapeutics, INC. | $21.91 | 2025 | Zoryve |
| Pfizer INC. | $20.66 | 2024 | |
| Astellas Pharma US INC | $19.96 | 2025 | Veozah |
| Allergan, INC. | $18.60 | 2021 | |
| Medtronic USA, INC. | $18.39 | 2019 | |
| Glaxosmithkline, LLC. | $17.86 | 2020 | |
| Alk-Abello, INC | $16.25 | 2020 | |
| Merck Sharp & Dohme LLC | $15.78 | 2021 | |
| Mayne Pharma Commercial LLC | $14.38 | 2025 | |
| Ethicon US, LLC | $13.65 | 2020 | |
| Biofrontera INC. | $13.56 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Ramachandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.